Etoposide: four decades of development of a topoisomerase II inhibitor
Tóm tắt
Từ khóa
Tài liệu tham khảo
Liu, 1994, DNA Topoisomerases: essential enzymes and lethal targets, Ann Rev Pharmacol Toxicol, 34, 191, 10.1146/annurev.pa.34.040194.001203
Froelich-Ammon, 1995, Topoisomerase poisons: harnessing the dark side of enzyme mechanisms, J Biol Chem, 270, 21429, 10.1074/jbc.270.37.21429
Wang, 1971, Interaction between DNA and E. coli: protein omega, J Mol Biol, 55, 523, 10.1016/0022-2836(71)90334-2
Gellert, 1976, An enzyme that introduces superhelical turns into DNA, Proc Natl Acad Sci USA, 73, 3872, 10.1073/pnas.73.11.3872
Slevin, 1991, The clinical pharmacology of etoposide, Cancer, 67, 319, 10.1002/1097-0142(19910101)67:1+<319::AID-CNCR2820671319>3.0.CO;2-D
King, 1946, The similarity of the effect of podophyllotoxin and colchicine and their use in the treatment of condylomata acuminata, Science, 104, 244, 10.1126/science.104.2698.244
Greenspan, 1950, Effect of alpha-peltatin, beta-peltatin and podophyllotoxin on lymphoma and other transplanted tumors, J Natl Cancer Inst, 10, 1273
Leiter J, Downing V, Hartwell J, et al. Damage induced in sarcoma 37 with podophyllin, podophyllotoxin, alpha-peltatin, beta-peltatin and quercetin. J Natl Cancer Inst 1950, 10, 1273–1293.
Stahelin, 1991, The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain Memorial Award Lecture, Cancer Res, 51, 5
Vogelzang, 1982, VP-16-214 (Etoposide). The mandrake root from Issyk-Kul, Am J Med, 72, 136, 10.1016/0002-9343(82)90600-3
Johnson, 1991, Current status of etoposide in the management of small cell lung cancer, Cancer, 67, 231, 10.1002/1097-0142(19910101)67:1+<231::AID-CNCR2820671305>3.0.CO;2-E
Radice, 1979, Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin’s lymphomas and other malignancies, Cancer Treat Rep, 63, 1231
Aisner, 1991, Etoposide: current and future status, Cancer, 67, 215, 10.1002/1097-0142(19910101)67:1+<215::AID-CNCR2820671302>3.0.CO;2-D
Muggia, 1991, New chemotherapies for ovarian cancer, Cancer, 67, 225, 10.1002/1097-0142(19910101)67:1+<225::AID-CNCR2820671304>3.0.CO;2-6
Ajani, 1991, Current strategies in the management of locoregional and metastatic gastric carcinoma, Cancer, 67, 260, 10.1002/1097-0142(19910101)67:1+<260::AID-CNCR2820671309>3.0.CO;2-2
Sledge, 1991, Etoposide in the management of metastatic breast cancer, Cancer, 67, 266, 10.1002/1097-0142(19910101)67:1+<266::AID-CNCR2820671310>3.0.CO;2-A
Fleming, 1989, Etoposide: an update, Clin Pharmacy, 8, 274
Loike, 1976, Effect of podophyllotoxin and VP-16 on microtubule assembly in vitro and nucleoside transport in HeLa cells, Biochemistry, 15, 5435, 10.1021/bi00670a003
Wozniak, 1983, DNA damage as a basis for 4-demethylepipodophyllotoxicity, Cancer Res, 43, 120
Schwinghammer, 1988, Cracking of ABS plastic devices used to infuse undiluted etoposide injection, Am J Hosp Pharm, 45, 1277
Creaven, 1975, EPEG, a new antineoplastic epipodophyllotoxin, Clin Pharmacol Ther, 18, 221, 10.1002/cpt1975182221
Hande, 1992, Etoposide pharmacology, Semin Oncol, 195, 3
D’Incalci M, Rossi C, Zucchetti M, et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 1986, 46, 2566–2571.
Creaven, 1997, PTG, a new antineoplastic epipodophyllotoxin, Clin Pharmacol Ther, 18, 227, 10.1002/cpt1975182227
Hande KR, Wedlund PJ, Noone RN, et al. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 1984, 44, 379–382.
Hande KR, Wolff SN, Greco FA, et al. Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol 1990, 8, 1101–1107.
Joel, 1996, Predicting etoposide toxicity: relationship to organ function and protein binding, J Clin Oncol, 14, 257, 10.1200/JCO.1996.14.1.257
Minami, 1996, Pharmacodynamic modeling of prolonged administration of etoposide, Cancer Chemother Pharmacol, 39, 61, 10.1007/s002800050538
Joel SP, Ellis P, O’Bymek, et al. Therapeutic monitoring of continuous etoposide in small cell lung cancer. J Clin Oncol 1996, 14, 1903–1912.
Zucchetti, 1995, Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer, Clin Cancer Res, 1, 1517
Thompson DS, Hainsworth JD, Hande KR, et al. Prolonged administration of low-dose infusional etoposide in patients with etoposide sensitive neoplasms: a phase I/II study. J Clin Oncol 1993, 11, 1322–1328.
Wolff SN, Grosh WW, Prater K, et al. In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy. Cancer Chemother Pharmacol 1987, 19, 246–249.
Drewinko, 1976, Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213, Cancer Treat Rep, 60, 1295
Heck MMS, Hittelman AN, Eamshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA, 1988, 85, 1086–1090.
Fox, 1990, Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone, Cancer Res, 50, 5813
Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989, 7, 1333–1340.
Clark PI, Slevin NE, Joel SP, et al. A randomized trial of two etoposide schedules in small cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 1994, 12, 1427–1435.
Hande KR, Krozely MG, Greco FA, et al. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993, 11, 374–377.
Joel SP, Clark RI, Heap L, et al. Pharmacological attempts to improve the bioavailability of oral etoposide. Cancer Chemother Pharmacol 1995, 37, 125–133.
Leu, 1995, Inhibition of intestinal p-glycoprotein and effects on etoposide absorption, Cancer Chemother Pharmacol, 35, 432, 10.1007/s002800050258
De Jong, 1995, Review of current clinical experience with prolonged (oral) etoposide in cancer treatment, Anticancer Res, 15, 2319
Hande, 1996, The importance of drug scheduling in cancer chemotherapy: etoposide as an example, Stem Cells, 14, 18, 10.1002/stem.140018
Miller AA, Herndon J, Hollis D, et al. Schedule dependency of 21 day oral versus 3 day intravenous etoposide in combination with intravenous cisplatin in extensive small cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995, 13, 1871–1879.
Girling, 1996, Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small cell lung cancer: a stopped multicenter randomized trial, Lancet, 348, 563, 10.1016/S0140-6736(96)02005-3
Budman DR, Igwemezie LN, Behr J, et al. Phase I evaluation of a water soluble etoposide prodrug, etoposide phosphate, given as a five minute infusion on days 1, 3, 5. J Clin Oncol 1994, 12, 1902–1909.
Thompson DS, Greco FA, Miller AA, et al. A phase I trial of etoposide phosphate administered as a daily 30 minute infusion for 5 days. Clin Pharmacol Ther 1995, 57, 499–507.
Kaul S, Igwemesie LN, Steward DJ, et al. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. J Clin Oncol 1995, 13, 2835–2841.
Schacter, 1996, Etoposide phosphate: what, why, where, and how?, Semin Oncol, 23, 1
Kreis W, Budman DR, Vinciguerra V, et al. Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2 hour infusion in patients with solid tumors. Cancer Chemother Pharmacol 1996, 38, 378–384.
Hainsworth JD, Levitan N, Wampler GL, et al. Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small cell lung cancer. J Clin Oncol 1995, 13, 1436–1442.
Doyle, 1996, A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer, Semin Oncol, 23, 51
Sessa C, Zucchetti M, Cerny T, et al. Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J Clin Oncol 1995, 13, 200–209.
Chabot GG, Armond JP, Terret C, et al. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. J Clin Oncol 1996, 44, 2020–2030.
Weiss, 1992, Hypersensitivity reaction, Semin Oncol, 19, 458
Pui CH, Riberiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphocytic leukemia. N Engl J Med 1991, 325, 1682–1687.
Tewey KM, Rowe TC, Yang L, et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984, 226, 446–468.
Bachur NR, Yu F, Johnson R, et al. Helicase inhibition by arthracycline anticancer agents. Mol Pharmacol 1992, 41, 993–998.
Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977, 197, 165–169.
Minotti, 1989, Adriamycin-dependent release of iron from microsomal membranes, Arch Biochem Biophys, 268, 398, 10.1016/0003-9861(89)90601-2
Goebel FD, Goldstein D, Goos M, et al. Efficacy and safety of stealth liposomal doxorubicin in AIDS-related Kaposi’s sarcoma. Brit J Cancer 1996, 73, 989–994.
Berman, 1993, A review of idarubicin in acute leukemia, Oncology, 7, 91
Feig SA, Ames MM, Sather HN, et al. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children’s Cancer Group. Med Ped Oncol 1996, 27, 505–514.
Lasot, 1994, Potential role of oral anthracyclines in older patients with cancer, Drugs & Aging, 4, 393
Steinherz LJ, Steinherz PG, Tan CD, et al. Cardiac complications 4 to 20 years after completing anthracycline therapy. JAMA 1991, 266, 1672–1677.
Swain, 1992, Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer, J Clin Oncol, 15, 1318, 10.1200/JCO.1997.15.4.1318
Faulds, 1991, Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer, Drugs, 41, 400, 10.2165/00003495-199141030-00007
Benjamin, 1995, Rationale for use of mitoxantrone in the older patient: cardiac toxicity, Semin Oncol, 22, 11
Cowan JD, Neidhardt J, McClure S, et al. Randomized trial of doxorubicin, bisantrene and mitoxantrone in advanced breast cancer: a Southwest Oncology Group Study. J Natl Cancer Inst 1991, 83, 1077–1084.
Stewart DJ, Evans WK, Shepherd FA, et al. Cyclophosphamide and fluorouracil combined with mitoxantrone vs doxorubicin for breast cancer: superiority of doxorubicin. J Clin Oncol 1997, 15, 1897–1905.
Posner LE, Dukart G, Goldberg J, et al. Mitoxantrone: an overview of safety and tolerance. Invest New Drugs 1985, 3, 123–132.
Sinha, 1995, Topoisomerase inhibitors: a review of their therapeutic potential in cancer, Drugs, 49, 11, 10.2165/00003495-199549010-00002